The clinical relevance of quality of life in heart failure patients with preserved ejection fraction - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/36510693/
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site. The site is secure....
Conclusions: EQ-5D-5L is useful tool for risk stratification in patients with HFpEF.
Share
Empagliflozin Proves Benefit in Pediatric Type 2 Diabetes in Phase 3 DINAMO Trial
New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes. Announced in a December 7 statement from Eli Lilly...
New data suggests empagliflozin (Jardiance) use was associated with significant improvements in glycemic control among pediatric patients with type 2 diabetes. This study, “Diabetes study of Linagliptin and Empagliflozin in Children and Adolescents,” was presented at the International Diabetes Federation World Diabetes Congress 2022.
Share
Therapeutic Efficacy of Shexiang Baoxin Pill Combined with Exercise in Patients with Heart Failure with Preserved Ejection Fraction: A Single-Center, Double-Blind, Randomized Controlled Trial - Chinese Journal of Integrative Medicine
Source : https://link.springer.com/article/10.1007/s11655-022-3627-3
Objective To evaluate the therapeutic efficacy of Shexiang Baoxin Pill combined with exercise in heart failure patients with preserved ejection fraction (HFpEF). Methods Sixty patients with HFpEF were randomly divided...
Conclusions: Exercise training improved exercise tolerance, sleep quality and quality of life (QoL) in patients with HFpEF. Notably, Shexiang Baoxin Pill played an active role in sleep quality and QoL of patients with HFpEF.
Share
/>
Conclusion: In EMPEROR-Preserved, empagliflozin was effective and safe without SBP meaningfully moderating empagliflozin’s treatment effects. This analysis of EMPEROR-Preserved shows that empagliflozin can be used safely and effectively without blood pressure being a meaningful moderator of the drug benefit.
Share
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis
Source : https://www.wjgnet.com/1949-8462/full/v14/i11/599.htm
Potential for sodium-glucose cotransporter-2 inhibitors in the management of metabolic syndrome: A systematic review and meta-analysis Abdulbaril Olagunju, Naser Yamani, Dorothy Kenny, Martina Mookadam, Farouk Mookadam, Samuel Unzek Abdulbaril Olagunju,...
Conclusion: SGLT2-Is have a promising role in the management of MetS.
Share